OTC Analgesic Additional Safety Labeling To Be Considered By NDAC
This article was originally published in The Tan Sheet
Executive Summary
Possible new labeling requirements and other initiatives designed to ensure the safety of OTC analgesics will be considered by FDA's Nonprescription Drugs Advisory Committee at a Sept. 19-20 meeting in Silver Spring, Md
You may also be interested in...
Ibuprofen Detailed Label Warnings Necessity Questioned By Wyeth
More explicit ibuprofen label warnings "may not necessarily prove to be as effective as the current more general warnings," Wyeth Consumer Healthcare asserts in background materials submitted for the upcoming NDAC meeting on analgesics safety
Naproxen Directly Linked To GI Bleeding In 32% Of Cases Reviewed By FDA
Nearly one-third of gastrointestinal hemorrhage cases related to OTC naproxen sodium use did not involve additional risk factors, FDA reports in a recently released postmarketing safety review
Ibuprofen Detailed Renal, GI Warnings Required For Monograph Inclusion
Clinical study data and adverse event reports support inclusion of a warning on OTC ibuprofen labeling to alert consumers at risk for developing acute renal failure to consult a doctor, FDA says